FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2954996679> ?p ?o ?g. }

• W2954996679 endingPage "888" @default.
• W2954996679 startingPage "876" @default.
• W2954996679 abstract "Most hepatitis C virus (HCV)-infected patients failing NS5A inhibitors develop resistance-associated substitutions (RASs). Here we report the use of resistance-guided retreatment of patients who failed prior NS5A inhibitor-containing regimens in the GEHEP-004 cohort. This is the largest direct-acting antiviral (DAA)-resistance cohort study conducted in Spain. We aim to provide indications on how to use resistance information in settings where sofosbuvir/velpatasvir/voxilaprevir may not be available.GEHEP-004 is a prospective multicenter cohort enrolling HCV-infected patients treated with interferon (IFN)-free DAA regimens. Prior to retreatment, population-based sequencing of HCV NS3, NS5A and NS5B genes was performed. After receiving a comprehensive resistance interpretation report, the retreatment regimen was chosen and the sustained virological response (SVR) at 12 weeks after treatment completion (SVR12) was recorded.A total of 342 patients experiencing virological failure after treatment with sofosbuvir/ledipasvir±ribavirin (54%), sofosbuvir/daclatasvir±ribavirin (23%), or paritaprevir-ritonavir/ombitasvir±dasabuvir±ribavirin (20%) were studied. After a resistance report, 186 patients were retreated. An SVR12 was achieved for 88.1% of the patients who failed after sofosbuvir/ledipasvir±ribavirin, 83.3% of the patients who failed after sofosbuvir/daclatasvir±ribavirin, 93.7% of the patients who failed after paritaprevir-ritonavir+ombitasvir±dasabuvir±ribavirin.In our study, we show how resistance-guided retreatment in conjunction with an interpreted report allows patients to achieve SVR rates close to 90%. We hypothesize that SVR rates may even be improved if resistance data are discussed between experienced virologists and treating clinicians. We believe that our data may be relevant for countries where the access to new DAA combination regimens is limited.Hepatitis C infection can be cured with currently available antiviral agents. Only a small proportion of patients experience treatment failure, however, in absolute numbers, a high number of patients may require retreatment. Highly effective combinations of antivirals are also available for retreatment. However, these antivirals might not be available in resource-limited settings. Herein, we show how, by analyzing the cause of resistance, retreatment efficacy with old drugs can get very close to the efficacy of new drug combinations." @default.
• W2954996679 created "2019-07-12" @default.
• W2954996679 creator A5003776429 @default.
• W2954996679 creator A5003827195 @default.
• W2954996679 creator A5004048701 @default.
• W2954996679 creator A5006610363 @default.
• W2954996679 creator A5009204097 @default.
• W2954996679 creator A5011612210 @default.
• W2954996679 creator A5016262404 @default.
• W2954996679 creator A5016745087 @default.
• W2954996679 creator A5018327981 @default.
• W2954996679 creator A5019435913 @default.
• W2954996679 creator A5019666393 @default.
• W2954996679 creator A5022666134 @default.
• W2954996679 creator A5025019704 @default.
• W2954996679 creator A5025127854 @default.
• W2954996679 creator A5025610151 @default.
• W2954996679 creator A5025836371 @default.
• W2954996679 creator A5028677580 @default.
• W2954996679 creator A5030144260 @default.
• W2954996679 creator A5031440229 @default.
• W2954996679 creator A5032071061 @default.
• W2954996679 creator A5032581412 @default.
• W2954996679 creator A5032911694 @default.
• W2954996679 creator A5033012471 @default.
• W2954996679 creator A5036118982 @default.
• W2954996679 creator A5036167547 @default.
• W2954996679 creator A5037901679 @default.
• W2954996679 creator A5038658043 @default.
• W2954996679 creator A5040524159 @default.
• W2954996679 creator A5043221422 @default.
• W2954996679 creator A5043609039 @default.
• W2954996679 creator A5043703197 @default.
• W2954996679 creator A5044127405 @default.
• W2954996679 creator A5045187400 @default.
• W2954996679 creator A5046798382 @default.
• W2954996679 creator A5046929024 @default.
• W2954996679 creator A5048817078 @default.
• W2954996679 creator A5049140504 @default.
• W2954996679 creator A5049736550 @default.
• W2954996679 creator A5051973157 @default.
• W2954996679 creator A5054609665 @default.
• W2954996679 creator A5054851035 @default.
• W2954996679 creator A5055406905 @default.
• W2954996679 creator A5055423100 @default.
• W2954996679 creator A5055910634 @default.
• W2954996679 creator A5055974683 @default.
• W2954996679 creator A5056087242 @default.
• W2954996679 creator A5060089579 @default.
• W2954996679 creator A5062408878 @default.
• W2954996679 creator A5063471364 @default.
• W2954996679 creator A5064151509 @default.
• W2954996679 creator A5065235949 @default.
• W2954996679 creator A5068966782 @default.
• W2954996679 creator A5070949389 @default.
• W2954996679 creator A5074314883 @default.
• W2954996679 creator A5077472923 @default.
• W2954996679 creator A5079506828 @default.
• W2954996679 creator A5079700165 @default.
• W2954996679 creator A5080436494 @default.
• W2954996679 creator A5081163611 @default.
• W2954996679 creator A5084333224 @default.
• W2954996679 creator A5084404678 @default.
• W2954996679 creator A5086437500 @default.
• W2954996679 creator A5086602983 @default.
• W2954996679 creator A5087474809 @default.
• W2954996679 creator A5088968622 @default.
• W2954996679 creator A5091853126 @default.
• W2954996679 date "2019-11-01" @default.
• W2954996679 modified "2023-10-18" @default.
• W2954996679 title "High efficacy of resistance-guided retreatment of HCV patients failing NS5A inhibitors in the real world" @default.
• W2954996679 cites W1826210767 @default.
• W2954996679 cites W2112024536 @default.
• W2954996679 cites W2185218296 @default.
• W2954996679 cites W2301065617 @default.
• W2954996679 cites W2318156787 @default.
• W2954996679 cites W2320330796 @default.
• W2954996679 cites W2397267618 @default.
• W2954996679 cites W2523075296 @default.
• W2954996679 cites W2527824850 @default.
• W2954996679 cites W2533110376 @default.
• W2954996679 cites W2575794989 @default.
• W2954996679 cites W2575880746 @default.
• W2954996679 cites W2591108500 @default.
• W2954996679 cites W2593495481 @default.
• W2954996679 cites W2617851912 @default.
• W2954996679 cites W2753744689 @default.
• W2954996679 cites W2754943124 @default.
• W2954996679 cites W2755773568 @default.
• W2954996679 cites W2769985632 @default.
• W2954996679 cites W2777870076 @default.
• W2954996679 cites W2794341756 @default.
• W2954996679 doi "https://doi.org/10.1016/j.jhep.2019.06.022" @default.
• W2954996679 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31279901" @default.
• W2954996679 hasPublicationYear "2019" @default.
• W2954996679 type Work @default.
• W2954996679 sameAs 2954996679 @default.
• W2954996679 citedByCount "12" @default.

• next